Is this you?
Request access for Nucleus Network with your @nucleusnetwork.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Nucleus Network
Unclaimed profileDCT Network · Melbourne, Australia (Global: US, UK) · ~1 sites
Intera lens
ICP 3Lift (cardio sample) 0.39Recruit soph 0.29
Quality Scorecard (1–100)
Overall68Recruit39Ops80Sponsor86Ther73
Performance (observed)
Historical trials
347
Completed
245
Terminated/Withdrawn
22
Completion rate
92%
Active now
72
Phase 2
34
Phase 3
6
Realized enrollment
78,170
First study year
2007
Years active
19
Match confidence
high
Enrollment velocity (inf)
4,114
Therapeutic
Areas
Early-phase (Phase I) clinical trials, pharmacokinetics, hepatic/renal studies
Specialties
Early-phase clinical research, global trials
Breadth (conditions)
261
Languages
English + Spanish (detected)
States
MN (US only)
Recruitment (web observed)
Trial Finder
Yes
Recruitment pages
Yes
SEO
Y
Capability notes
50-bed Phase I facility in Minneapolis; specialized in-patient recruitment
Relationships
Sponsors
Pfizer; Syneos Health; BeiGene; Gilead Sciences; ModernaTX, Inc.; Galera Therapeutics, Inc.
CROs
IQVIA Pty Ltd; Novotech (Australia) Pty Limited; Oncocross Australia Pty Ltd.; Premier Research; Syneos Health; Syneos Heath
Owner / parent
Blackstone (acquired Oct 2021)
Acquisitions
Hammersmith Medicines Research (2025)
Expansion
Acquired Hammersmith Medicines Research (Aug 2025)
Capacity & people
Investigators
—
Coordinators
—
CEO
Teena Pisarev
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Tech & DCT
eSource
Yes
Builds tech
Internal facility operations
DCT / decentralized
Y
Tech stack
Unknown
Recruiting visible
Y
Notes
Global early-phase specialist with limited US footprint (single Minneapolis facility). PE-backed but focused on Phase I in-patient studies, not multi-site recruitment. Poor Intera fit.
Recommendation features (sample indication)
Ind fit 0.55Liftability 0.39Overall68
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.